{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:53:02Z","timestamp":1792601582809,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T00:00:00Z","timestamp":1576195200000},"content-version":"vor","delay-in-days":1107,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["RO1 CA-194042"],"award-info":[{"award-number":["RO1 CA-194042"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","journals.elsevierhealth.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Pathology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.ajpath.2016.08.020","type":"journal-article","created":{"date-parts":[[2016,10,17]],"date-time":"2016-10-17T21:10:32Z","timestamp":1476738632000},"page":"3225-3235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":342,"title":["Hypophysitis Secondary to Cytotoxic T-Lymphocyte\u2013Associated Protein 4 Blockade"],"prefix":"10.1016","volume":"186","author":[{"given":"Patrizio","family":"Caturegli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Di Dalmazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Grosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Benjamin","family":"Larman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatianna","family":"Larman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Taverna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirco","family":"Cosottini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Lupi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpath.2016.08.020_bib1","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1210\/jc.2010-2970","article-title":"IgG4-related hypophysitis: a new addition to the hypophysitis spectrum","volume":"96","author":"Leporati","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ajpath.2016.08.020_bib2","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1210\/jc.2013-1912","article-title":"From Japan with love: another tessera in the hypophysitis mosaic","volume":"98","author":"Caturegli","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ajpath.2016.08.020_bib3","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/er.2004-0011","article-title":"Autoimmune hypophysitis","volume":"26","author":"Caturegli","year":"2005","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ajpath.2016.08.020_bib4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/BF02738885","article-title":"Xanthomatous hypophysitis: a novel entity of obscure etiology","volume":"10","author":"Deodhare","year":"1999","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.ajpath.2016.08.020_bib5","doi-asserted-by":"crossref","first-page":"896","DOI":"10.7326\/0003-4819-141-11-200412070-00033","article-title":"Multiple pseudotumors in IgG4-associated multifocal systemic fibrosis","volume":"141","author":"van der Vliet","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ajpath.2016.08.020_bib6","first-page":"1499","article-title":"Necrotizing infundibulo-hypophysitis: a unique syndrome of diabetes insipidus and hypopituitarism","volume":"76","author":"Ahmed","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ajpath.2016.08.020_bib7","doi-asserted-by":"crossref","first-page":"8372","DOI":"10.1073\/pnas.1533209100","article-title":"Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma","volume":"100","author":"Phan","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2016.08.020_bib8","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1586\/eem.09.37","article-title":"Autoimmune hypophysitis: expanding the differential diagnosis to CTLA-4 blockade","volume":"4","author":"Gutenberg","year":"2009","journal-title":"Expert Rev Endocrinol Metab"},{"key":"10.1016\/j.ajpath.2016.08.020_bib9","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EJE-14-0845","article-title":"Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma","volume":"172","author":"Albarel","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ajpath.2016.08.020_bib10","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ajpath.2016.08.020_bib11","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","article-title":"Systemic high dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study","volume":"21","author":"Min","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2016.08.020_bib12","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2016.08.020_bib13","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1\u00a0antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2016.08.020_bib14","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2217\/fon.15.222","article-title":"Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis","volume":"12","author":"Abdel-Rahman","year":"2016","journal-title":"Future Oncol"},{"key":"10.1016\/j.ajpath.2016.08.020_bib15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.ajpath.2016.08.020_bib16","article-title":"Economic burden of toxicities associated with treating metastatic melanoma in\u00a0eight countries","author":"Wehler","year":"2015","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.ajpath.2016.08.020_bib17","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3111\/13696998.2012.739226","article-title":"Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis","volume":"16","author":"Barzey","year":"2013","journal-title":"J Med Econ"},{"key":"10.1016\/j.ajpath.2016.08.020_bib18","first-page":"551","article-title":"MR height of the pituitary gland as a function of age and sex: especially physiological hypertrophy in adolescence and in climacterium","volume":"18","author":"Tsunoda","year":"1997","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.ajpath.2016.08.020_bib19","doi-asserted-by":"crossref","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of ctla-4 mediates hypophysitis secondary to administration of ctla-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ajpath.2016.08.020_bib20","article-title":"Pituitary antibodies in an adolescent with secondary adrenal insufficiency and Turner\u00a0syndrome","author":"Pollock","year":"2016","journal-title":"Hormone Res Paediatr"},{"key":"10.1016\/j.ajpath.2016.08.020_bib21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.yexmp.2012.05.008","article-title":"LMP2, a novel immunohistochemical marker to distinguish renal oncocytoma from the eosinophilic variant of chromophobe renal cell carcinoma","volume":"94","author":"Zheng","year":"2013","journal-title":"Exp Mol Pathol"},{"issue":"Suppl 1","key":"10.1016\/j.ajpath.2016.08.020_bib22","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.2500\/aap.2012.33.3561","article-title":"Classification of hypersensitivity reactions","volume":"33","author":"Uzzaman","year":"2012","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.ajpath.2016.08.020_bib23","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights","volume":"19","author":"Faje","year":"2015","journal-title":"Pituitary"},{"key":"10.1016\/j.ajpath.2016.08.020_bib24","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cen.13063","article-title":"Immune checkpoint inhibitor related hypophysitis and endocrine dysfunction: clinical review","volume":"85","author":"Joshi","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ajpath.2016.08.020_bib25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ajpath.2016.08.020_bib26","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S2213-8587(15)00008-X","article-title":"Effect of cancer treatment on hypothalamic-pituitary function","volume":"3","author":"Crowne","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ajpath.2016.08.020_bib27","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/ajco.12348","article-title":"Early recognition of ipilimumab-related autoimmune hypophysitis in patients with metastatic melanoma: case studies and recommendations for management","volume":"11","author":"Tiu","year":"2015","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.ajpath.2016.08.020_bib28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4137\/CMED.S22469","article-title":"Immune checkpoint inhibitor therapy associated hypophysitis","volume":"8","author":"Mahzari","year":"2015","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"10.1016\/j.ajpath.2016.08.020_bib29","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1182\/blood-2011-11-388918","article-title":"Basis of CTLA-4 function in regulatory and conventional CD4(+) T cells","volume":"119","author":"Tai","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2016.08.020_bib30","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/annrheumdis-2014-206297","article-title":"Interaction between innate immunity and Ro52-induced antibody causes Sjogren's syndrome-like disorder in mice","volume":"75","author":"Szczerba","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ajpath.2016.08.020_bib31","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.0105-2896.2005.00249.x","article-title":"CTLA4 gene polymorphism and autoimmunity","volume":"204","author":"Gough","year":"2005","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ajpath.2016.08.020_bib32","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1200\/JCO.2005.01.128","article-title":"Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma","volume":"23","author":"Sanderson","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajpath.2016.08.020_bib33","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/CJI.0b013e31817fd8f3","article-title":"Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade","volume":"31","author":"Breunis","year":"2008","journal-title":"J Immunother"}],"container-title":["The American Journal of Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944016303790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944016303790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T07:12:28Z","timestamp":1576221148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002944016303790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0002944016303790"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpath.2016.08.020","relation":{},"ISSN":["0002-9440"],"issn-type":[{"value":"0002-9440","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypophysitis Secondary to Cytotoxic T-Lymphocyte\u2013Associated Protein 4 Blockade","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpath.2016.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 American Society for Investigative Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}